PL1937721T3 - Przeciwciała anty-IL23 - Google Patents
Przeciwciała anty-IL23Info
- Publication number
- PL1937721T3 PL1937721T3 PL06802075T PL06802075T PL1937721T3 PL 1937721 T3 PL1937721 T3 PL 1937721T3 PL 06802075 T PL06802075 T PL 06802075T PL 06802075 T PL06802075 T PL 06802075T PL 1937721 T3 PL1937721 T3 PL 1937721T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- antigen
- binding portions
- subunit
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71133605P | 2005-08-25 | 2005-08-25 | |
US77235506P | 2006-02-10 | 2006-02-10 | |
PCT/US2006/032752 WO2007024846A2 (en) | 2005-08-25 | 2006-08-23 | Anit-il-23 antibiodies |
EP06802075A EP1937721B1 (en) | 2005-08-25 | 2006-08-23 | Anti-il-23 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1937721T3 true PL1937721T3 (pl) | 2010-12-31 |
Family
ID=37616511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06802075T PL1937721T3 (pl) | 2005-08-25 | 2006-08-23 | Przeciwciała anty-IL23 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7872102B2 (pl) |
EP (1) | EP1937721B1 (pl) |
JP (1) | JP5022367B2 (pl) |
KR (1) | KR101028200B1 (pl) |
AT (1) | ATE475672T1 (pl) |
AU (1) | AU2006283194B9 (pl) |
BR (1) | BRPI0615018A2 (pl) |
CA (1) | CA2619052A1 (pl) |
CY (1) | CY1110792T1 (pl) |
DE (1) | DE602006015830D1 (pl) |
DK (1) | DK1937721T3 (pl) |
EA (1) | EA013506B1 (pl) |
ES (1) | ES2347690T3 (pl) |
HK (1) | HK1119712A1 (pl) |
IL (1) | IL188312A0 (pl) |
MX (1) | MX2008002179A (pl) |
NO (1) | NO20081465L (pl) |
PL (1) | PL1937721T3 (pl) |
PT (1) | PT1937721E (pl) |
SI (1) | SI1937721T1 (pl) |
WO (1) | WO2007024846A2 (pl) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201902033T4 (tr) | 2005-06-30 | 2019-03-21 | Janssen Biotech Inc | Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları. |
US7807160B2 (en) * | 2005-08-31 | 2010-10-05 | Schering Corporation | Engineered anti-IL-23 antibodies |
MX2008008621A (es) | 2005-12-29 | 2008-11-27 | Centocor Inc | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos. |
US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
EP2064242A1 (en) * | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
HUE042172T2 (hu) * | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
NZ579297A (en) | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
PT2187964E (pt) * | 2007-08-10 | 2015-01-14 | Regeneron Pharma | Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
WO2009068630A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
CN102369285B (zh) * | 2008-11-12 | 2014-06-18 | 默沙东公司 | 用于增强的抗-IGF1R表达的βGl-IgG内含子 |
US20110250644A1 (en) | 2008-12-19 | 2011-10-13 | Schering Corporation | Feed supplement for mammalian cell culture and methods of use |
JP2012522749A (ja) | 2009-04-01 | 2012-09-27 | グラクソ グループ リミテッド | 抗il−23免疫グロブリン |
EP2435480A1 (en) * | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
US20120269765A1 (en) * | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
WO2011079004A1 (en) | 2009-12-23 | 2011-06-30 | Schering Corporation | Cell line 3m |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
CA3017116A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
EP2583979B1 (en) | 2011-10-19 | 2015-12-16 | Effimune | Methods to prepare antibodies directed against p19 subunit of human IL-23 |
ES2908474T3 (es) | 2012-05-03 | 2022-04-29 | Boehringer Ingelheim Int | Anticuerpos anti-IL-23p19 |
US9708401B2 (en) | 2012-05-22 | 2017-07-18 | Bristol-Myers Squibb Company | IL-17A/F cross-reactive monoclonal antibodies and methods of using the same |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
TWI636063B (zh) | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合il-23之抗體 |
EA201591579A1 (ru) | 2013-03-15 | 2016-01-29 | Амген Инк. | Способы лечения болезни крона при помощи анти-il-23 антитела |
AU2014238148A1 (en) | 2013-03-15 | 2015-10-08 | Amgen Inc. | Methods for treating psoriasis using an anti-IL-23 antibody |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
EA201791734A1 (ru) | 2015-02-04 | 2018-01-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения воспалительных заболеваний |
MX2017013156A (es) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim Int | Metodos para tratar enfermedades. |
JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
CN108472367A (zh) | 2015-12-22 | 2018-08-31 | 美国安进公司 | 作为对il23拮抗剂的临床应答的预测因子的ccl20 |
MX2018012410A (es) | 2016-04-15 | 2019-02-21 | Boehringer Ingelheim Int | Metodos para tratar enfermedades inflamatorias. |
EP3848390A1 (en) | 2016-10-14 | 2021-07-14 | Boehringer Ingelheim International GmbH | Methods of treating diseases |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
KR20210032441A (ko) | 2018-07-13 | 2021-03-24 | 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 | 브라지쿠맙을 이용한 궤양성 대장염의 치료 |
MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
CN112807428A (zh) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
CN114773466B (zh) * | 2020-11-26 | 2023-08-29 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3045480B2 (ja) * | 1996-12-20 | 2000-05-29 | 大同メタル工業株式会社 | ボーリング盤 |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
ATE474849T1 (de) * | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
JP4505166B2 (ja) * | 1999-09-09 | 2010-07-21 | シェーリング コーポレイション | 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用 |
WO2004071517A2 (en) * | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
DK1601694T3 (da) * | 2003-03-10 | 2009-12-14 | Schering Corp | Anvendelser af IL23-antagonister, relaterede reagenser |
BRPI0507794A (pt) * | 2004-02-17 | 2007-07-17 | Schering Corp | métodos de modular a atividade de il-23, reagentes relacionados |
MX2008008621A (es) * | 2005-12-29 | 2008-11-27 | Centocor Inc | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos. |
JP5286287B2 (ja) * | 2007-02-22 | 2013-09-11 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 骨発達を促進するための組成物及び方法 |
-
2006
- 2006-08-23 EA EA200800417A patent/EA013506B1/ru not_active IP Right Cessation
- 2006-08-23 AT AT06802075T patent/ATE475672T1/de active
- 2006-08-23 DE DE602006015830T patent/DE602006015830D1/de active Active
- 2006-08-23 WO PCT/US2006/032752 patent/WO2007024846A2/en active Application Filing
- 2006-08-23 BR BRPI0615018-7A patent/BRPI0615018A2/pt not_active IP Right Cessation
- 2006-08-23 MX MX2008002179A patent/MX2008002179A/es active IP Right Grant
- 2006-08-23 DK DK06802075.9T patent/DK1937721T3/da active
- 2006-08-23 ES ES06802075T patent/ES2347690T3/es active Active
- 2006-08-23 PL PL06802075T patent/PL1937721T3/pl unknown
- 2006-08-23 PT PT06802075T patent/PT1937721E/pt unknown
- 2006-08-23 AU AU2006283194A patent/AU2006283194B9/en not_active Ceased
- 2006-08-23 CA CA002619052A patent/CA2619052A1/en not_active Abandoned
- 2006-08-23 EP EP06802075A patent/EP1937721B1/en not_active Not-in-force
- 2006-08-23 KR KR1020087004323A patent/KR101028200B1/ko not_active IP Right Cessation
- 2006-08-23 JP JP2008528064A patent/JP5022367B2/ja not_active Expired - Fee Related
- 2006-08-23 US US11/997,597 patent/US7872102B2/en not_active Expired - Fee Related
- 2006-08-23 SI SI200630791T patent/SI1937721T1/sl unknown
-
2007
- 2007-12-20 IL IL188312A patent/IL188312A0/en unknown
-
2008
- 2008-03-25 NO NO20081465A patent/NO20081465L/no not_active Application Discontinuation
- 2008-10-14 HK HK08111347.9A patent/HK1119712A1/xx not_active IP Right Cessation
-
2010
- 2010-09-23 CY CY20101100855T patent/CY1110792T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20090240036A1 (en) | 2009-09-24 |
EP1937721A2 (en) | 2008-07-02 |
DE602006015830D1 (de) | 2010-09-09 |
ES2347690T3 (es) | 2010-11-03 |
AU2006283194A1 (en) | 2007-03-01 |
CA2619052A1 (en) | 2007-03-01 |
BRPI0615018A2 (pt) | 2011-04-26 |
ATE475672T1 (de) | 2010-08-15 |
KR101028200B1 (ko) | 2011-04-11 |
JP5022367B2 (ja) | 2012-09-12 |
CY1110792T1 (el) | 2015-06-10 |
SI1937721T1 (sl) | 2010-11-30 |
AU2006283194B9 (en) | 2011-02-03 |
EA013506B1 (ru) | 2010-06-30 |
AU2006283194B8 (en) | 2010-10-28 |
EA200800417A1 (ru) | 2008-06-30 |
DK1937721T3 (da) | 2010-10-18 |
WO2007024846A2 (en) | 2007-03-01 |
AU2006283194B2 (en) | 2010-10-21 |
NO20081465L (no) | 2008-05-15 |
HK1119712A1 (en) | 2009-03-13 |
PT1937721E (pt) | 2010-09-17 |
IL188312A0 (en) | 2008-04-13 |
KR20080031450A (ko) | 2008-04-08 |
WO2007024846A3 (en) | 2007-06-07 |
EP1937721B1 (en) | 2010-07-28 |
JP2009506041A (ja) | 2009-02-12 |
US7872102B2 (en) | 2011-01-18 |
MX2008002179A (es) | 2008-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL188312A0 (en) | Anti-il-23 antibodies | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
TW200740844A (en) | Novel MAdCAM antibodies | |
MX2009006891A (es) | Anticuerpos cd44. | |
TW200626171A (en) | Fixed dosing of HER antibodies | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
NO20084878L (no) | Humanisert C-kit antistoff | |
MY156315A (en) | Anti-vegf antibodies | |
EA200970874A1 (ru) | Антитела против склеростина | |
WO2009026117A3 (en) | Novel compounds | |
WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
MX2009006471A (es) | Anticuerpo anti especifico de linfopoyetina estromal timica de diseño. | |
MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
MX2010005871A (es) | Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. | |
WO2011004028A3 (en) | Tlr3 binding agents | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 |